Epstein File EFTA00447984: Session and CI (DS9)

Epstein Index›Documents›EFTA00447984

💨IMPACT LEVEL 1 — MEH

Epstein File EFTA00447984: Session and CI (DS9)

General DocumentDate unavailableEFTA004479841 keyword hits

0

views

0

shares

0

reactions

0

persons

2

keywords

4

excerpts

This document contains scientific research data from the FOURIER study on PCSK9 Inhibition presented at the 2017 American College of Cardiology Scientific Session in Washington, D.C. The excerpt includes clinical trial endpoints and confidence intervals (CI) for evolocumab versus placebo groups, with specific patient numbers and statistical measures. The document is a medical research presentation unrelated to the Epstein case.

👤 Named in This Document

No named persons linked yet

🔑 Evidence Keywords

session CI

📋 Key Excerpts4

PersonKeyword

Excerpt 1

Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk (FOURIER) study, presented at the 2017 American College of Cardiology Scientific **Session**

Excerpt 2

Presented at: American College of Cardiology 2017 Scientific **Session** in Washington, D.C.

Excerpt 3

For the primary study endpoint (which occurred in 1,344 patients in the evolocumab group and 1,563 in the placebo group; HR, 0.85; 95% **CI**, 0.79-0.92; P